Marinomed Biotech AG
Research Marinomed Biotech AG (MARI.VI) on Bullrun: market cap EUR 8.00M, P/E 0.4. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMARI.VI
- ExchangeVI
- CountryAustria
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 8.00M
- P/E0.4
- Financial periodFY2025
- RevenueEUR 7.69M
- Revenue growth62.0%
- Net incomeEUR 18.02M
- Free cash flow-EUR 1.10M
- Gross margin81.5%
Valuation Snapshot
latest market cap is EUR 8.00M; P/E is 0.4.
Peer valuation comparison
Latest P/E is 0.41x versus a Healthcare sector median of 24.6x (98.3% below).
Latest P/E is 0.41x versus a Austria median of 17.72x (97.7% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 7.69M | EUR 18.02M | -EUR 1.10M | 81.5% | 9.76 | EUR 951.78K | EUR 11.40M | -EUR 7.05M |
| FY2024 | EUR 4.75M | -EUR 15.42M | -EUR 2.40M | 20.6% | -8.64 | EUR 1.71M | EUR 28.23M | -EUR 26.16M |
| FY2023 | EUR 9.06M | -EUR 6.37M | -EUR 3.70M | 10.8% | -4.16 | EUR 2.56M | EUR 20.39M | -EUR 12.60M |
| FY2022 | EUR 11.28M | -EUR 6.40M | -EUR 5.43M | 19.0% | -4.28 | EUR 8.18M | EUR 22.63M | -EUR 4.16M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-04 | EUR 8.00M | 0.4 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Marinomed Biotech AG
Marinomed Biotech AG operates as a biopharmaceutical company in Austria, other European countries, and internationally. Its lead products include Budesolv for the treatment of allergic rhinitis in late-stage clinical development; and Tacrosolv for the treatment of inflammatory eye diseases in Phase II clinical studies. The company also develops Satiasolv for pain immune reactions in the preclinical development phase. In addition, it provides Solv4U for formulation development and biopharmaceutical testing services.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Marinomed Biotech AG's market cap?
Marinomed Biotech AG's market capitalization is EUR 8.00M.
What is Marinomed Biotech AG's P/E ratio?
Marinomed Biotech AG's price-to-earnings (P/E) ratio is 0.4.
What does Marinomed Biotech AG do?
Marinomed Biotech AG operates as a biopharmaceutical company in Austria, other European countries, and internationally. Its lead products include Budesolv for the treatment of allergic rhinitis in late-stage clinical development; and Tacrosolv for the treatment of inflammatory eye diseases in Phase II clinical studies. The company also develops Satiasolv for pain immune reactions in the preclinical development phase. In addition, it provides Solv4U for formulation development and biopharmaceutical testing services.